AU2004212305A1 - Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention - Google Patents

Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention Download PDF

Info

Publication number
AU2004212305A1
AU2004212305A1 AU2004212305A AU2004212305A AU2004212305A1 AU 2004212305 A1 AU2004212305 A1 AU 2004212305A1 AU 2004212305 A AU2004212305 A AU 2004212305A AU 2004212305 A AU2004212305 A AU 2004212305A AU 2004212305 A1 AU2004212305 A1 AU 2004212305A1
Authority
AU
Australia
Prior art keywords
dipyridamole
angiotensin
stroke
antagonist
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004212305A
Other languages
English (en)
Inventor
James C. Gilbert
Lutz Hilbrich
David Michael Humphreys
Axel Riedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004212305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2004212305A1 publication Critical patent/AU2004212305A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004212305A 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention Abandoned AU2004212305A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (de) 2003-02-13 2003-02-13 Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
DE10306179.7 2003-02-13
EP03018212 2003-08-08
EP03018212.5 2003-08-08
PCT/EP2004/001208 WO2004071385A2 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention

Publications (1)

Publication Number Publication Date
AU2004212305A1 true AU2004212305A1 (en) 2004-08-26

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004212305A Abandoned AU2004212305A1 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention

Country Status (29)

Country Link
US (5) US20040214802A1 (enExample)
EP (2) EP1733729A1 (enExample)
JP (1) JP2006517557A (enExample)
KR (1) KR20050100676A (enExample)
CN (1) CN1750830A (enExample)
AR (1) AR043173A1 (enExample)
AT (1) ATE395921T1 (enExample)
AU (1) AU2004212305A1 (enExample)
BR (1) BRPI0407457A (enExample)
CA (1) CA2515941A1 (enExample)
DE (2) DE10306179A1 (enExample)
DK (1) DK1603573T3 (enExample)
EA (1) EA200501231A1 (enExample)
EC (1) ECSP055963A (enExample)
ES (1) ES2308147T3 (enExample)
HR (1) HRP20050713A2 (enExample)
MX (1) MXPA05008572A (enExample)
NO (1) NO20054216L (enExample)
NZ (1) NZ542302A (enExample)
PE (1) PE20050191A1 (enExample)
PL (1) PL378204A1 (enExample)
PT (1) PT1603573E (enExample)
RS (1) RS20050618A (enExample)
SI (1) SI1603573T1 (enExample)
TW (1) TW200501957A (enExample)
UA (1) UA83481C2 (enExample)
UY (1) UY28182A1 (enExample)
WO (1) WO2004071385A2 (enExample)
ZA (1) ZA200505956B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
TWI725008B (zh) * 2015-01-28 2021-04-21 瑞采生技有限公司 用於增強ＰＰＡＲγ表現及核轉位之化合物及其醫療用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
EP1013273A1 (en) 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
JP2002293742A (ja) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd 鎮痛・抗炎症剤
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe

Also Published As

Publication number Publication date
PL378204A1 (pl) 2006-03-20
MXPA05008572A (es) 2005-11-04
DK1603573T3 (da) 2008-09-15
BRPI0407457A (pt) 2006-01-31
US20040214802A1 (en) 2004-10-28
NO20054216D0 (no) 2005-09-12
EP1603573A2 (en) 2005-12-14
SI1603573T1 (sl) 2008-10-31
AR043173A1 (es) 2005-07-20
EP1733729A1 (en) 2006-12-20
ES2308147T3 (es) 2008-12-01
EP1603573B1 (en) 2008-05-21
RS20050618A (sr) 2007-09-21
US20060241089A1 (en) 2006-10-26
HRP20050713A2 (en) 2006-09-30
UY28182A1 (es) 2004-09-30
NZ542302A (en) 2008-12-24
DE10306179A1 (de) 2004-08-26
EP1603573B8 (en) 2009-04-01
TW200501957A (en) 2005-01-16
CA2515941A1 (en) 2004-08-26
NO20054216L (no) 2005-09-12
WO2004071385A2 (en) 2004-08-26
UA83481C2 (uk) 2008-07-25
CN1750830A (zh) 2006-03-22
US20080188497A1 (en) 2008-08-07
ATE395921T1 (de) 2008-06-15
PT1603573E (pt) 2008-06-26
DE602004013937D1 (de) 2008-07-03
WO2004071385A3 (en) 2005-01-06
JP2006517557A (ja) 2006-07-27
ZA200505956B (en) 2006-03-29
US20070004687A1 (en) 2007-01-04
ECSP055963A (es) 2006-01-16
EA200501231A1 (ru) 2006-02-24
PE20050191A1 (es) 2005-04-12
KR20050100676A (ko) 2005-10-19
US20080113949A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
US20080113949A1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
JP5757677B2 (ja) 門脈圧亢進症の予防及び／又は治療
CZ20023381A3 (cs) Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
HUP0203249A2 (hu) Dipiridamol és mopidamol alkalmazása fibrinfüggő mikrokeringési rendellenességek kezelésére és megelőzésére szolgáló gyógyszer készítésére
KR20060007034A (ko) 혈전색전증 질환 및 트롬빈의 과형성 및/또는 트롬빈수용체의 상승된 발현에 의해 유발된 질환 및 장애를치료하고 예방하기 위한, 디피리다몰 또는 모피다몰의 용도
Melian et al. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
US20090075949A1 (en) Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
CA2566081A1 (en) Use of dipyridamole for treatment of resistance to platelet inhibitors
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
US20080275011A1 (en) Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
KR20050018330A (ko) 혈관장애의 치료 및 예방을 위한 디피리다몰,아세틸살리실산 및 안지오텐신 ⅱ 길항제의 용도
JP2005060359A (ja) 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
HK1089941A (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
AU2003235004A1 (en) Use of dipyridamole, acetylsalicylic acid and an angiotensin II antagonist for treatment and prevention of vascular events
MXPA03007462A (es) Uso de dipiridamol, acido acetilsalicilico y un antagonista de la angiotensina ii para el tratamiento y la prevencion de eventos vasculares.
WO2009080301A1 (en) Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
Van Dyke et al. Drugs Used in Gout
TW200522965A (en) Novel pharmaceutical combination comprising pyrimido-pyrimidine in combination with one other active component for treatment and prevention of fibrin-dependent microcirculation disorders

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application